干扰素γ诱导蛋白 30：从生物学功能到癌症的潜在治疗靶点。
Interferon Gamma Inducible Protein 30: from biological functions to potential therapeutic target in cancers.
发表日期：2024 Aug 14
作者：
Sen Zhang, Liwen Ren, Wan Li, Yizhi Zhang, Yihui Yang, Hong Yang, Fang Xu, Wanxin Cao, Xiaoxue Li, Xu Zhang, Guanhua Du, Jinhua Wang
来源：
Cellular & Molecular Immunology
摘要：
干扰素γ诱导蛋白30 (IFI30)，也称为γ干扰素诱导溶酶体硫醇还原酶(GILT)，主要存在于溶酶体和细胞质中。作为唯一被确定可催化内吞途径中二硫键还原的酶，IFI30 通过减少内吞蛋白的二硫键，有助于主要组织相容性复合物 (MHC) I 类限制性抗原交叉呈递和 MHC II 类限制性抗原加工。值得注意的是，新兴研究表明 IFI30 参与肿瘤发生、肿瘤发展和肿瘤免疫反应。以IFI30为靶点可能为癌症治疗提供新策略并改善患者预后。该综述全面综述了IFI30在肿瘤进展、细胞氧化还原状态、自噬、肿瘤免疫反应、药物敏感性等方面的研究进展，以期为IFI30在肿瘤治疗尤其是免疫治疗中的药理干预提供理论依据。 .© 2024。施普林格自然瑞士股份公司。
Interferon Gamma Inducible Protein 30 (IFI30), also known as Gamma-Interferon-Inducible Lysosomal Thiol Reductase (GILT), is predominantly found in lysosomes and the cytoplasm. As the sole enzyme identified to catalyze disulfide bond reduction in the endocytic pathway, IFI30 contributes to both major histocompatibility complex (MHC) class I-restricted antigen cross-presentation and MHC class II-restricted antigen processing by decreasing the disulfide bonds of endocytosed proteins. Remarkably, emerging research has revealed that IFI30 is involved in tumorigenesis, tumor development, and the tumor immune response. Targeting IFI30 may provide new strategies for cancer therapy and improve the prognosis of patients. This review provided a comprehensive overview of the research progress on IFI30 in tumor progression, cellular redox status, autophagy, tumor immune response, and drug sensitivity, with a view to providing the theoretical basis for pharmacological intervention of IFI30 in tumor therapy, particularly in immunotherapy.© 2024. Springer Nature Switzerland AG.